NCT06830044Phase 3Recruiting

Evaluation of Efficacy and Safety of Milsaperidone as Adjunctive Therapy in Patients With Major Depressive Disorder

Study sponsor: Vanda Pharmaceuticals

Primary completion is the date data collection ends for the main study measures, not when results are published.

Primary completion2028-03Estimated
Enrollment · participants500Estimated
Source updated2026-09-24Last update listed in the registry record

Changes to this trial

Last 12 months
Filters
Clear filters
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.

Explore older trial changes

Upgrade to Pro to see the full available history for this trial.

Upgrade to Pro Illustrative preview